-
Annals of Surgery Feb 1974
Topics: Adult; Aged; Diagnosis, Differential; Extremities; Female; Glomus Tumor; Hemangiopericytoma; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retroperitoneal Neoplasms; Thoracoscopy
PubMed: 4359454
DOI: 10.1097/00000658-197402000-00002 -
American Journal of Ophthalmology Case... Mar 2022To report a unique presentation of hemangiopericytoma and discuss the clinical course, pathological features, and management of this tumor.
PURPOSE
To report a unique presentation of hemangiopericytoma and discuss the clinical course, pathological features, and management of this tumor.
OBSERVATIONS
An otherwise healthy 54-year-old Caucasian female presented with a painless conjunctival mass. The lesion gradually enlarged over a three-week period and was unresponsive to corticosteroid treatment. The mass was surgically removed, and histopathologic findings were consistent with hemangiopericytoma.
CONCLUSIONS AND IMPORTANCE
Conjunctival hemangiopericytoma should be considered in patients with conjunctival lesions unresponsive to medical management. Surgical excision is diagnostic and therapeutic and is the strongest predictor of clinical course. Incompletely excised lesions are at a greater risk of local recurrence and subsequent metastasis. Given the neoplasm's malignant potential, patients should be followed in the outpatient setting.
PubMed: 35112030
DOI: 10.1016/j.ajoc.2022.101308 -
BioMed Research International 2020Hemangiopericytomas are rare tumors derived from pericytes surrounding the blood vessels. The clinicopathological characteristics and prognosis of hemangiopericytoma...
BACKGROUND
Hemangiopericytomas are rare tumors derived from pericytes surrounding the blood vessels. The clinicopathological characteristics and prognosis of hemangiopericytoma patients remain mostly unknown. In this retrospective cohort study, we assessed the clinicopathological characteristics of hemangiopericytoma patients, as well as the clinical usefulness of different treatment modalities. . We collected the clinicopathological data (between 1975 and 2016) of hemangiopericytoma and hemangioendothelioma patients from the Surveillance, Epidemiology, and End Results (SEER) database. Incidence, treatment, and patient prognosis were assessed.
RESULTS
Data from 1474 patients were analyzed in our study cohort (hemangiopericytoma: = 1243; hemangioendothelioma: = 231). The incidence of hemangiopericytoma in 2016 was 0.060 per 100,000 individuals. The overall survival (OS) and cancer-specific survival (CSS) did not differ between patients with hemangioendothelioma and those with hemangiopericytoma ( = 0.721, = 0.544). The tumor grade had no effect on the OS of hemangiopericytoma patients. Multivariate analysis revealed the clinical usefulness of surgery in hemangiopericytoma patients (HR = 0.15, 95% confidence interval: 0.05-0.41, < 0.001). In contrast, radiotherapy did not improve OS ( = 0.497) or CSS ( = 0.584), and chemotherapy worsened patient survival ( < 0.001). Additionally, the combination of surgery and radiotherapy had a similar effect with surgery alone on hemangiopericytoma patient survival (OS: = 0.900; CSS: = 0.156). Surgery plus chemotherapy provided a worse clinical benefit than surgery alone ( < 0.001).
CONCLUSIONS
Our findings suggested that hemangiopericytoma had a similar prognosis with hemangioendothelioma. Surgery was the only effective treatment that provided survival benefits in hemangiopericytoma patients, while the clinical usefulness of adjuvant chemotherapy or radiotherapy was limited.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Female; Hemangioendothelioma; Hemangiopericytoma; Humans; Incidence; Infant; Male; Middle Aged; Prognosis; Retrospective Studies; SEER Program; Survival Analysis; Treatment Outcome; United States; Young Adult
PubMed: 33204688
DOI: 10.1155/2020/2468320 -
Proceedings (Baylor University. Medical... Apr 2016Here we report the case of a 57-year-old man who underwent resection of a dural-based hemangiopericytoma (HPC) in the left frontoparietal region. The patient was treated...
Here we report the case of a 57-year-old man who underwent resection of a dural-based hemangiopericytoma (HPC) in the left frontoparietal region. The patient was treated with radiation therapy and remained symptom-free for 10 years. At 67 years of age, he presented with a mass in the left frontal region near the same area as the first tumor, in addition to a separate smaller mass in the right middle cranial fossa. Resection of the larger left frontal mass revealed an HPC. Follow-up imaging 9 months later showed a significant increase in size of the right middle cranial fossa mass. This third mass was resected, and histological examination also demonstrated an HPC.
PubMed: 27034566
DOI: 10.1080/08998280.2016.11929413 -
Actas Dermo-sifiliograficas Jan 2021
Topics: Humans; Myopericytoma
PubMed: 33053369
DOI: 10.1016/j.ad.2019.02.032 -
Archives of Pathology & Laboratory... Jun 2018Solitary fibrous tumor (SFT) is a unique mesenchymal neoplasm that was originally believed to be of submesothelial origin. Eventually, SFT expanded to include what was... (Review)
Review
Solitary fibrous tumor (SFT) is a unique mesenchymal neoplasm that was originally believed to be of submesothelial origin. Eventually, SFT expanded to include what was previously called hemangiopericytoma in other regions of the body that had similar immunohistochemical and morphologic features. Although most are benign, many studies have tried to identify histologic features that predict which tumors will behave in an aggressive manner. Recently, dedifferentiation has been described in rare cases of SFT and does appear to correlate with a more aggressive clinical course. Dedifferentiated SFT occurs in a similar age range and location as conventional SFT and can resemble multiple different malignant entities. Utilization of ancillary studies and thorough tissue sampling is important to reach the correct diagnosis. The morphologic features, immunohistochemistry, molecular alterations, and prognosis will be discussed.
Topics: Cell Dedifferentiation; Hemangiopericytoma; Humans; Immunohistochemistry; Prognosis; Solitary Fibrous Tumors
PubMed: 29848035
DOI: 10.5858/arpa.2016-0570-RS -
Indian Journal of Otolaryngology and... Apr 2004Hemangiopericytomas are very rare soft tissue tumors of vascular origin featurding pericyts distributed around vascular spaces. They have unpredictable biological...
Hemangiopericytomas are very rare soft tissue tumors of vascular origin featurding pericyts distributed around vascular spaces. They have unpredictable biological behavior and a high local recurrence rate. Silver reticulin stain is essential for their histologic diagnosis. Approximately one third occur in the head and neck. Metastases occurs in nearly one half of all cases. They are relatively radioresistant despite their great vascular component. Wide local excision of the lesion, whenever feasible and lifelong follow-up should be the treatment of choice.
PubMed: 23120063
DOI: 10.1007/BF02974328 -
BMJ Case Reports Jun 2017A 55-year-old woman, diagnosed with a renal mass by abdominal ultrasonography (USG) in an external medical centre, presented to our hospital. The medical history was...
A 55-year-old woman, diagnosed with a renal mass by abdominal ultrasonography (USG) in an external medical centre, presented to our hospital. The medical history was unremarkable except for diabetes mellitus and hypertension. The haemogram and urine tests were normal. The only pathology revealed in routine biochemistry tests was increased glucose level (164 mg/dL). The repeat USG performed in our hospital revealed a solid hypoechoic mass lesion approximately 4 cm in diameter closely adjacent to the right kidney. At Doppler ultrasonography, the tumour demonstrated intense vascularisation. An abdominal CT scan was performed to characterise the lesion. The CT scan revealed a 42Ã-39 mm mass lesion with regular contours adjacent to the right kidney. In the arterial phase, the tumour demonstrated intense enhancement and in the delayed phase the images showed washout (figure 1). The patient underwent surgery and after histopathological examination retroperitoneal haemangiopericytoma was diagnosed and no relapse or distant organ metastasis was detected throughout the 2-year follow-up.
Topics: Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Hemangiopericytoma; Humans; Hypertension; Middle Aged; Retroperitoneal Space; Tomography, X-Ray Computed; Ultrasonography, Doppler, Color
PubMed: 28611143
DOI: 10.1136/bcr-2017-220945 -
Acta Medica Portuguesa Feb 1995A case of hemangiopericytoma located in the left upper thigh is presented. The literature is reviewed, particularly the clinical aspects and reference is made to...
A case of hemangiopericytoma located in the left upper thigh is presented. The literature is reviewed, particularly the clinical aspects and reference is made to arteriography and preoperative embolization.
Topics: Female; Hemangiopericytoma; Humans; Middle Aged; Radiography; Soft Tissue Neoplasms; Thigh
PubMed: 7771212
DOI: No ID Found -
Journal of Neurological Surgery. Part... Jun 2019Solitary fibrous tumors (SFT) and hemangiopericytomas (HPC) are now classified along a single spectrum of fibroblastic mesenchymal tumors with NAB2-STAT6 fusion....
Solitary fibrous tumors (SFT) and hemangiopericytomas (HPC) are now classified along a single spectrum of fibroblastic mesenchymal tumors with NAB2-STAT6 fusion. This fusion acts as a driver mutation that constitutively activates EGR1, which is known to be involved in the p16 pathway. Overexpression of p16 is associated with malignancy and worse prognosis in multiple mesenchymal tumors. The authors sought to investigate p16 immunoexpression in association with malignancy and prognosis of SFT/HPC tumors. Twenty-three SFT/HPC tumors (central nervous system [CNS]: 12, non CNS: 11) diagnosed at our institution from 2002 to 2016 were assigned into 3 grades. Data from microarray immunohistochemistry for STAT6, synaptophysin, CD56, chromogranin, SST2A, EGR1, Ki67, and p16, grade and survival were analyzed. CNS SFT/HPCs tend to be malignant (grade 3; 67 vs. 18%, = 0.036) and more likely to express synaptophysin (33 vs. 0%, = 0.035) than non CNS tumors. Overexpression of p16 (immunopositivity ≥ 50% tumor cells) was associated with malignant (grade 3) tumors, and has a sensitivity of 70% (7/10), and a specificity of 77% (10/13), as a predictive marker for malignancy. SFT/HPC patients with low p16 expression demonstrated significantly longer disease-free survival time (median survival > 113 months) than those with high p16 expression (median survival = 30 months, = 0.045). SFT/HPCs in the CNS are more likely to be malignant than the tumors in other sites. High p16 expression is also associated with malignancy and shorter disease-free survival time in SFT/HPC tumors in our study cohort. Clinically, p16 overexpression can be used as predictive marker for malignancy and prognosis and a possible therapeutic target.
PubMed: 31143564
DOI: 10.1055/s-0038-1669419